Starting Wednesday, July 1, Medicare will cover GLP-1 obesity drugs for the first time in the program’s history — a watershed development that could unlock millions of new patients for Novo Nordisk (NVO) and Eli Lilly (LLY). Eligible beneficiaries can access weight-loss drugs like Wegovy and Zepbound for a flat $50 monthly copay under Medicare’s new Bridge demonstration program, dramatically undercutting the out-of-pocket prices patients currently pay.
The scale of the opportunity is enormous. There are more than 69 million Medicare beneficiaries, and the Centers for Medicare and Medicaid Services expect “several million” to access drugs through the Bridge program. Novo Nordisk and Eli Lilly both estimate that 15 million to 20 million older adults in Medicare qualify for weight-loss treatment. That compares to a market that has barely scratched the surface of eligible patients so far. For context, Novo’s Wegovy currently retails between $199 and $399 per month depending on dosage — the $50 Medicare copay represents a 75%-to-87% cost reduction for patients. There’s an important caveat: the Bridge program is an 18-month demonstration, set to expire at the end of 2027 unless the Trump administration extends or replaces it, creating uncertainty for patients who start these typically lifelong therapies.
For investors in NVO and LLY, this represents a near-term volume catalyst. Even if only 2 million to 3 million of the eligible population enrolls in the first year, that’s a significant new revenue stream layered on top of already strong demand. Both stocks have pulled back from their 2024 peaks amid competition concerns and reimbursement uncertainty — this development resolves one of the biggest overhangs. Watch for Q3 earnings from both companies to see early enrollment data. Investors bullish on the GLP-1 trend might also consider ETFs with pharma exposure, but the clearest plays remain NVO and LLY directly.
